On August 25, 2026, Novartis made a significant announcement: its radioligand therapy drug, Pluvicto® (lutetium Lu 177 vipivotide tetraxetan injection), received approval from the National Medical Products Administration (NMPA) for a new indication. Specifically, it can now be used in combination with androgen receptor pathway inhibitors to treat prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC). Notably, Pluvicto® had already secured approval in China for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This latest approval represents a further broadening of Pluvicto®'s clinical applications in China, encompassing multiple crucial treatment stages, spanning from mCRPC to mHSPC.